Targeted Sprouty1 overexpression in cardiac myocytes does not alter myocardial remodeling or function

Nathan J. Charles, Robert C Huebert, Sangjin Lee, Neeta Adhikari, Sean Polster, James E. Rider, Elizabeth Braunlin, Ami Mariash, Maggie Robledo, David Schuweiler, Jennifer L. Hall

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The mitogen activated protein kinase (MAPK) signaling pathway regulates multiple events leading to heart failure including ventricular remodeling, contractility, hypertrophy, apoptosis, and fibrosis. The regulation of conserved intrinsic inhibitors of this pathway is poorly understood. We recently identified an up-regulation of Sprouty1 (Spry1) in a targeted approach for novel inhibitors of the MAPK signaling pathway in failing human hearts following reverse remodeling. The goal of this study was to test the hypothesis that up-regulated expression of Spry1 in cardiac myocytes would be sufficient to inhibit ERK1/2 activation and tissue remodeling. We established a murine model with up-regulated Spry1 expression in cardiac myocytes using the alpha-myosin heavy chain promoter (α-MHC). Heart weight and cardiac myocyte morphology were unchanged in adult male α-MHC-Spry1 mice compared to control mice. Ventricular function of α-MHC-Spry1 mice was unaltered at 8 weeks or 1 year of age. These findings were consistent with the lack of an effect of Spry1 on ERK1/2 activity. In summary, targeted up-regulation of Spry1 in cardiac myocytes is not sufficient to alter cell or tissue remodeling consistent with the lack of an effect on ERK1/2 activity.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalMolecular and Cellular Biochemistry
Volume342
Issue number1-2
DOIs
StatePublished - Sep 2010

Fingerprint

Cardiac Myocytes
Mitogen-Activated Protein Kinases
Tissue
Ventricular Myosins
Up-Regulation
Myosin Heavy Chains
Ventricular Remodeling
Ventricular Function
Chemical activation
Hypertrophy
Apoptosis
Fibrosis
Heart Failure
Weights and Measures

Keywords

  • Echocardiography
  • MAPkinase
  • Myocyte
  • Spry1

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Targeted Sprouty1 overexpression in cardiac myocytes does not alter myocardial remodeling or function. / Charles, Nathan J.; Huebert, Robert C; Lee, Sangjin; Adhikari, Neeta; Polster, Sean; Rider, James E.; Braunlin, Elizabeth; Mariash, Ami; Robledo, Maggie; Schuweiler, David; Hall, Jennifer L.

In: Molecular and Cellular Biochemistry, Vol. 342, No. 1-2, 09.2010, p. 57-62.

Research output: Contribution to journalArticle

Charles, NJ, Huebert, RC, Lee, S, Adhikari, N, Polster, S, Rider, JE, Braunlin, E, Mariash, A, Robledo, M, Schuweiler, D & Hall, JL 2010, 'Targeted Sprouty1 overexpression in cardiac myocytes does not alter myocardial remodeling or function', Molecular and Cellular Biochemistry, vol. 342, no. 1-2, pp. 57-62. https://doi.org/10.1007/s11010-010-0468-8
Charles, Nathan J. ; Huebert, Robert C ; Lee, Sangjin ; Adhikari, Neeta ; Polster, Sean ; Rider, James E. ; Braunlin, Elizabeth ; Mariash, Ami ; Robledo, Maggie ; Schuweiler, David ; Hall, Jennifer L. / Targeted Sprouty1 overexpression in cardiac myocytes does not alter myocardial remodeling or function. In: Molecular and Cellular Biochemistry. 2010 ; Vol. 342, No. 1-2. pp. 57-62.
@article{7a78f018ff3747b1ab55ce608ceb784d,
title = "Targeted Sprouty1 overexpression in cardiac myocytes does not alter myocardial remodeling or function",
abstract = "The mitogen activated protein kinase (MAPK) signaling pathway regulates multiple events leading to heart failure including ventricular remodeling, contractility, hypertrophy, apoptosis, and fibrosis. The regulation of conserved intrinsic inhibitors of this pathway is poorly understood. We recently identified an up-regulation of Sprouty1 (Spry1) in a targeted approach for novel inhibitors of the MAPK signaling pathway in failing human hearts following reverse remodeling. The goal of this study was to test the hypothesis that up-regulated expression of Spry1 in cardiac myocytes would be sufficient to inhibit ERK1/2 activation and tissue remodeling. We established a murine model with up-regulated Spry1 expression in cardiac myocytes using the alpha-myosin heavy chain promoter (α-MHC). Heart weight and cardiac myocyte morphology were unchanged in adult male α-MHC-Spry1 mice compared to control mice. Ventricular function of α-MHC-Spry1 mice was unaltered at 8 weeks or 1 year of age. These findings were consistent with the lack of an effect of Spry1 on ERK1/2 activity. In summary, targeted up-regulation of Spry1 in cardiac myocytes is not sufficient to alter cell or tissue remodeling consistent with the lack of an effect on ERK1/2 activity.",
keywords = "Echocardiography, MAPkinase, Myocyte, Spry1",
author = "Charles, {Nathan J.} and Huebert, {Robert C} and Sangjin Lee and Neeta Adhikari and Sean Polster and Rider, {James E.} and Elizabeth Braunlin and Ami Mariash and Maggie Robledo and David Schuweiler and Hall, {Jennifer L.}",
year = "2010",
month = "9",
doi = "10.1007/s11010-010-0468-8",
language = "English (US)",
volume = "342",
pages = "57--62",
journal = "Molecular and Cellular Biochemistry",
issn = "0300-8177",
publisher = "Springer Netherlands",
number = "1-2",

}

TY - JOUR

T1 - Targeted Sprouty1 overexpression in cardiac myocytes does not alter myocardial remodeling or function

AU - Charles, Nathan J.

AU - Huebert, Robert C

AU - Lee, Sangjin

AU - Adhikari, Neeta

AU - Polster, Sean

AU - Rider, James E.

AU - Braunlin, Elizabeth

AU - Mariash, Ami

AU - Robledo, Maggie

AU - Schuweiler, David

AU - Hall, Jennifer L.

PY - 2010/9

Y1 - 2010/9

N2 - The mitogen activated protein kinase (MAPK) signaling pathway regulates multiple events leading to heart failure including ventricular remodeling, contractility, hypertrophy, apoptosis, and fibrosis. The regulation of conserved intrinsic inhibitors of this pathway is poorly understood. We recently identified an up-regulation of Sprouty1 (Spry1) in a targeted approach for novel inhibitors of the MAPK signaling pathway in failing human hearts following reverse remodeling. The goal of this study was to test the hypothesis that up-regulated expression of Spry1 in cardiac myocytes would be sufficient to inhibit ERK1/2 activation and tissue remodeling. We established a murine model with up-regulated Spry1 expression in cardiac myocytes using the alpha-myosin heavy chain promoter (α-MHC). Heart weight and cardiac myocyte morphology were unchanged in adult male α-MHC-Spry1 mice compared to control mice. Ventricular function of α-MHC-Spry1 mice was unaltered at 8 weeks or 1 year of age. These findings were consistent with the lack of an effect of Spry1 on ERK1/2 activity. In summary, targeted up-regulation of Spry1 in cardiac myocytes is not sufficient to alter cell or tissue remodeling consistent with the lack of an effect on ERK1/2 activity.

AB - The mitogen activated protein kinase (MAPK) signaling pathway regulates multiple events leading to heart failure including ventricular remodeling, contractility, hypertrophy, apoptosis, and fibrosis. The regulation of conserved intrinsic inhibitors of this pathway is poorly understood. We recently identified an up-regulation of Sprouty1 (Spry1) in a targeted approach for novel inhibitors of the MAPK signaling pathway in failing human hearts following reverse remodeling. The goal of this study was to test the hypothesis that up-regulated expression of Spry1 in cardiac myocytes would be sufficient to inhibit ERK1/2 activation and tissue remodeling. We established a murine model with up-regulated Spry1 expression in cardiac myocytes using the alpha-myosin heavy chain promoter (α-MHC). Heart weight and cardiac myocyte morphology were unchanged in adult male α-MHC-Spry1 mice compared to control mice. Ventricular function of α-MHC-Spry1 mice was unaltered at 8 weeks or 1 year of age. These findings were consistent with the lack of an effect of Spry1 on ERK1/2 activity. In summary, targeted up-regulation of Spry1 in cardiac myocytes is not sufficient to alter cell or tissue remodeling consistent with the lack of an effect on ERK1/2 activity.

KW - Echocardiography

KW - MAPkinase

KW - Myocyte

KW - Spry1

UR - http://www.scopus.com/inward/record.url?scp=77955854274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955854274&partnerID=8YFLogxK

U2 - 10.1007/s11010-010-0468-8

DO - 10.1007/s11010-010-0468-8

M3 - Article

VL - 342

SP - 57

EP - 62

JO - Molecular and Cellular Biochemistry

JF - Molecular and Cellular Biochemistry

SN - 0300-8177

IS - 1-2

ER -